Copyright: ©Author(s) 2026.
World J Gastroenterol. May 7, 2026; 32(17): 117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823
Table 3 The correlation between autoantibodies and tumor and inflammatory indicators
| Characteristics | Negative (n = 67) | Positive (n = 163) | U value | P value |
| CEA (ng/mL), median (IQR) | 37.46 (30.80, 41.74) | 30.64 (24.16, 38.34) | 3648 | < 0.001 |
| CA199 (U/mL), median (IQR) | 45.32 (35.43, 58.40) | 35.74 (27.80, 41.54) | 2888 | < 0.001 |
| NLR, median (IQR) | 8.15 (5.51, 9.46) | 5.713 (4.93, 6.34) | 2812 | < 0.001 |
| PLR, median (IQR) | 222.4 (156.0, 363.9) | 195.1 (106.5, 310.2) | 4333 | 0.014 |
| PIV, median (IQR) | 1263 (1140, 1357) | 1255 (957.0, 1408) | 5458 | 0.996 |
| SII, median (IQR) | 1400 (917.4, 1844) | 1377 (765.3, 2324) | 5362 | 0.831 |
- Citation: Zheng PM, Ouyang LB, Wang R, Jing KY, Gao HJ, Zhu CK. Clinical significance of autoantibody profiling and systemic inflammation in predicting outcomes of gastric cancer patients undergoing immunotherapy. World J Gastroenterol 2026; 32(17): 117823
- URL: https://www.wjgnet.com/1007-9327/full/v32/i17/117823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i17.117823